home > drugs a-z list > somavert (pegvisomant) drug center > somavert (pegvisomant) drug - overdosage and contraindications

In one reported incident of acute overdose with SOMAVERT (pegvisomant) during pre-marketing clinical studies, a patient self-administered 80 mg/day for seven days. The patient experienced a slight increase in fatigue, had no other complaints, and demonstrated no significant clinical laboratory abnormalities. In cases of overdose, administration of SOMAVERT (pegvisomant) should be discontinued and not resumed until IGF-I levels return to within or above the normal range.

Drug Abuse And Dependence

Available data do not demonstrate drug-abuse potential or psychological dependence with SOMAVERT. Radiolabeled pegvisomant does not cross the blood-brain barrier in rats.

SOMAVERT (pegvisomant) is contraindicated in patients with a history of hypersensitivity to any of its components. The stopper on the vial of SOMAVERT (pegvisomant) contains latex.

Last reviewed on RxList: 8/13/2010
This monograph has been modified to include the generic and brand name in many instances.